Title: An international Prospective, Open-label, Multi-Center, Randomized Phase III Study comparing lutetium (177LU) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (PSMA DC 2302)
- Principal Investigator: Dr. Medhat Osman
- Study Coordinators: Lindsey Vargo
The purpose of this study is to evaluate the efficacy of AAA617 versus observation after Stereotactic Body Radiation Therapy (SBRT), in delaying castration or disease recurrence in adult patients with PSMA positive OMPC with 1 to 5 metastatic lesions detected by PSMA PET using gallium (68Ga) gozetotide or piflufolastat (18F), negative for M1 disease by conventional imaging (CI).
This study is administered by VREF and funded by Novartis.
Find Out More
This study is currently enrolling patients. To learn more about PSMA DC 2302 and how you can join contact our research office at (314) 289-7690.
If you are a veteran receiving care through the VA St. Louis Health Care System and believe you may be eligible for this study, please speak with your Physician. For general information about our research, please visit our main Clinical Trials page or contact us directly.